ArticleClinical and experimental nephrology2014
Budget impact analysis of chronic kidney disease mass screening test in Japan.
Article in Clinical and experimental nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Evidence-practice gaps in chronic kidney disease management among patients taking antidiabetic or antihypertensive medications: a nationwide analysis of Japanese primary care electronic health records.Clinical and experimental nephrology · 2026Observational
- Random forest model used to predict the medical out-of-pocket costs of hypertensive patients.Frontiers in public health · 2024Article
- Behaviour modification intervention for patients with chronic kidney disease could provide a mid- to long-term reduction in public health care expenditure: budget impact analysis.Clinical and experimental nephrology · 2022Article
- Higher cardiovascular mortality in men with persistent dipstick hematuria.Clinical and experimental nephrology · 2021Article
- Impact of Metabolic Syndrome on the Mortality Rate among Participants in a Specific Health Check and Guidance Program in Japan.Internal medicine (Tokyo, Japan) · 2020Article
- Usefulness of the quantitative measurement of urine protein at a community-based health checkup: a cross-sectional study.Clinical and experimental nephrology · 2020Article
- Trace proteinuria by dipstick screening is associated with metabolic syndrome, hypertension, and diabetes.Clinical and experimental nephrology · 2018Article
- Dipstick proteinuria and all-cause mortality among the general population.Clinical and experimental nephrology · 2018Article
- Glucosuria and all-cause mortality among general screening participants.Clinical and experimental nephrology · 2018Article
- Global overview of health systems oversight and financing for kidney care.Kidney international supplements · 2018Review
- The First Report on the Frequency of Asymptomatic Proteinuria in Iranian School-aged Children.Advanced biomedical research · 2018Article
- Mortality risk among screened subjects of the specific health check and guidance program in Japan 2008-2012.Clinical and experimental nephrology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur recently published cost-effectiveness study on chronic kidney disease mass screening test in Japan evaluated the use of dipstick test, serum creatinine (Cr) assay or both in specific health checkup (SHC). Mandating the use of serum Cr assay additionally, or the continuation of current policy mandating dipstick test only was found cost-effective. This study aims to examine the affordability of previously suggested reforms.
methodsBudget impact analysis was conducted assuming the economic model would be good for 15 years and applying a population projection. Costs expended by social insurers without discounting were counted as budgets.
resultsAnnual budget impacts of mass screening compared with do-nothing scenario were calculated as ¥79-¥-1,067 million for dipstick test only, ¥2,505-¥9,235 million for serum Cr assay only and ¥2,517-¥9,251 million for the use of both during a 15-year period. Annual budget impacts associated with the reforms were calculated as ¥975-¥4,129 million for mandating serum Cr assay in addition to the currently used mandatory dipstick test, and ¥963-¥4,113 million for mandating serum Cr assay only and abandoning dipstick test.
conclusionsEstimated values associated with the reform from ¥963-¥4,129 million per year over 15 years are considerable amounts of money under limited resources. The most impressive finding of this study is the decreasing additional expenditures in dipstick test only scenario. This suggests that current policy which mandates dipstick test only would contain medical care expenditure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.